Nanofármacos

ANTIBODY SPECIFICALLY BINDING TO CLAUDIN18.2 AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2024188341A1

Provided is an anti-Claudin18.2 nanobody or a binding fragment thereof. The antibody has good specificity, and immune effector cells targeting Claudin18.2 which are prepared from the antibody show a good therapeutic effect in treating or ameliorating diseases having positive expression of Claudin18.2.

NANO-FORMULATION, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: WO2024187640A1

A nano-formulation, a preparation method therefor, and use thereof. The nano-formulation is prepared by loading an anti-cancer drug β-elemene by a DSPE-PEG-coated stanene nanosheet (STNSP). The STNSP and β-elemene can effectively polarize tumor-promoting M2 tumor-associated macrophages (TAMs) into a tumor-suppressive M1 phenotype by means of activating an active oxygen-related signaling pathway, that is, an immune cell population is activated by means of inducing M2-to-M1 polarization of the TAMs, thereby triggering an anti-tumor immune response. The STNSP and β-elemene also have a synergistic effect, so that B16F10 melanoma cells can be selectively killed, thereby enhancing the anti-tumor efficacy.

MULTI-METAL NANOCOMPOSITES

Resumen de: WO2024191143A1

The present invention relates to multiple-complex-structured nanocomposites of various metals, and a preparation method therefor, the nanocomposites being for enhancing the functionality of antibiotics or antibiofilms.

COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY OF THERAPEUTICS AND USES THEREOF

Resumen de: AU2023233811A1

The present specification discloses pharmaceutical composition disclosed herein comprises one or more fibrates, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C

CELLULOSE NANOCRYSTAL-BASED EMULSIONS AND USES THEREOF

Resumen de: US2024306636A1

This invention relates generally to cellulose nanocrystal-based emulsions that can serve as a spray adjuvant for improved agrochemical application efficiency. More particularly, the cellulose nanocrystal-based emulsions are nanocellulose-stabilized Pickering emulsions having a semi-liquid formulation of colloidal cellulose nanocrystals and biopolymers that can substitute currently used surfactants and drift reducing agents in agrochemicals. The cellulose nanocrystal-based emulsions are suitable with both water soluble and oil soluble active ingredient chemistries, and the shear characteristics of the emulsions make them suitable for oil in water-based spray applications. Droplet size distribution can be tuned by changing the ingredient concentrations, thus helping control particle drift. Moreover, a stable cross-linked network formation facilitates the entrapment and encapsulation of volatile agrochemical chemistries, thus preventing their volatilization and reducing vapor drift.

RNA STABILIZING NANOPARTICLES

Resumen de: US2024307552A1

The present disclosure provides ZnO-based compositions that stabilize mRNA and RNA as well as provide compositions and therapies to treat or prevent cancer and viral as well as microbial diseases.

NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT

Resumen de: US2024307321A1

The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use.

COMPOSITIONS AND USES THEREOF IN TREATING CANCERS

Resumen de: US2024307318A1

Disclosed herein is a composition comprising a lipid nanoparticle and a double-stranded oligodeoxynucleotide (dsODN) encapsulated in the lipid nanoparticle. According to the embodiments of the present disclosure, the dsODN comprises two strands complementary to each other, in which the first strand comprises the nucleotide sequence of SEQ ID NO: 1. Also disclosed herein are methods of treating cancers by using the present composition.

PORPHYRIN NANOVESICLE WITH FATTY ACID CONJUGATE

Resumen de: US2024307308A1

There is described herein a bilayer nanovesicle comprising porphyrin-phospholipid conjugate and a chelator-fatty acid conjugate; wherein the chelator-fatty acid conjugate comprises an aminopolycarboxylic acid conjugated to a single chain fatty acid; and the porphyrin-phospholipid conjugate comprises one porphyrin, porphyrin derivative or porphyrin analog covalently attached to a lipid side chain, preferably at the sn-1 or the sn-2 position, of one phospholipid.

SELF-ASSEMBLED NANOPARTICLE CONTAINING gHgL PROTEIN OF EB VIRUS, PREPARATION METHOD AND USE THEREOF

Resumen de: US2024309050A1

Disclosed is a self-assembled nanoparticle containing a gHgL protein of an EB virus, a preparation method and use thereof. The self-assembled nanoparticle comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises a gHgL protein and a first vector subunit, and the second polypeptide comprises a second vector subunit; the first vector subunit is 153-50A1, and the second vector subunit is 153-50B.4PT1; and the gHgL protein is linked to the first vector subunit through a linker. The gHgL protein of the EB virus is displayed on a surface of the self-assembled nanoparticle for the first time. The self-assembled nanoparticle has a larger particle size than the antigen (gHgL), a better antigen residence volume, and a thermal stability comparable to the antigen (gHgL). Moreover, since a larger number of gHgLs are displayed, the self-assembled nanoparticle can strongly stimulate more B cells and induce higher antibody titer.

TGF- B receptor II isoform, fusion peptide, methods of treatment and methods in vitro

Resumen de: US2024309063A1

An isoform of the TGF beta receptor II having a sequence of about of 80 amino acids and lacking a transmembrane domain. The isoform having the amino acid sequence set forth in SEQ ID No. 12. The isoform may have the amino acid sequence set forth in SEQ ID No. 2 or sequences having at least 85% sequence identity to the sequence set forth in SEQ ID No. 2. A fusion peptide is provided having an isoform of the TGF beta II receptor fused to a ligand, wherein a vector having the fusion peptide is used to treat cancer and/or hepatic fibrosis. An antibody binding the soluble isoform of the TGF beta II receptor is provided. The antibody binds the amino acid sequence shown in SEQ ID No. 12 and is used in in vitro methods.

LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS

Resumen de: US2024308952A1

Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

RNA VACCINES AGAINST INFECTIOUS DISEASES

Resumen de: US2024307521A1

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Methods of using these compositions as a vaccine for treatment of an infectious disease are also provided.

Fermented Uni-sourced Nanoemulsion of Nigella sativa or Cannabis sativa For Use in Medical, Cosmetic, and Recreational Indications with a Method of Its Production and Use

Resumen de: US2024307474A1

A botanical uni-sourced drug-loaded lipid-based nanoemulsion produced from one single medicinal herb such as Nigella sativa, Cannabis sativa, or Curcuma longa, wherein the herb acts as a comprehensive provider for the bioactive phytochemicals, oil phase, saponin surfactant, co-surfactant, proteins, and carbohydrates to produce the uni-sourced safe, clear, stable lipid-based drug delivery system. The nanoemulsion can be formulated into oral dosage form including nanoemulsion, microemulsion and liposomes, wherein the extraction and emulsification are carried out by the addition of water-soluble organic solvent, wherein the product can be further fermented and esterified for improved stability, wherein Nigella sativa uni-sourced nanocompositions are used as first-in-class oral formulation to relax coily hair targeting the arrector pili muscle in the hair root, anticancer, anti-tuberculosis, anti-COVID-19; and antiviral treatment, Cannabis nanocompositions are used for medical or recreational purposes, and Curcuma longa is used for nutraceutical and treatment purposes.

DELIVERY OF GENE EDITING SYSTEMS AND METHODS OF USE THEREOF

Resumen de: WO2024192291A1

The present disclosure describes improved LNP-based nucleobase editing systems and therapeutics for use in treating a disease. In particular, the disclosure describes improved LNPs, including novel and improved ionic lipids for making LNPs, that enhance the targeted delivery of LNP-based nucleobase editing systems and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced nucleobase editing systems and/or therapeutic agents.

NANOPARTICLE FORMULATIONS FOR A NON-OPIOID DRUG

Resumen de: WO2024191741A1

This disclosure is directed to a nanoparticle formulation for N,N-Diethyl-2-(N-(2-(4-hydroxyphenylamino)-2-oxoethyl)sulfamoyl)benzamide (SRP-3D (DA)), an active pharmaceutical ingredient that is insoluble in water and cannot be dissolved in any injection-safe vehicle to a sufficient concentration for dosing. Also encompassed by the disclosure are nanoparticulate suspension comprising a nanoparticulate SRP-3D (DA) (or SRP-3D (DA) nanoparticles), a wetting agent and a cryoprotectant. The nanoparticulate compositions comprise SRP-3D (DA) particles having an average particle size of less than about 500 nm or less than about 300 nm.

NANOPARTICLES FOR DELIVERY OF THERAPEUTICS TO THE EYE FOR TREATMENT OF GLAUCOMA

Resumen de: US2024307358A1

The present invention provides systems for targeted delivery of therapeutic agents to Schlemm's canal (SC) endothelial cells. Also provided are methods for using the systems to treat glaucoma or reduce intraocular pressure.

脂質ナノ粒子製剤

Resumen de: AU2022328856A1

The present invention is directed to lipid nanoparticles, formulations containing lipid nanoparticles and methods of treating diseases or conditions with said lipid nanoparticles and formulations thereof. A lipid nanoparticle comprising (a) an active agent; (b) a cationic and/or ionisable lipid comprising from about 40 mol % to about 60 mol % of the total lipid present in the nanoparticle; (c) a phospholipid comprising from about 5 mol % to about 20 mol % of the total lipid present in the nanoparticle; (d) a structural lipid comprising from about 30 mol % to about 50 mol % of the total lipid present in the nanoparticle; (e) a PEGylated lipid comprising from about 0.05 mol % to less than 0.5 mol % of the total lipid present in the nanoparticle.

NANOPARTICULATE FORMULATION

抗腫瘍薬を含む組成物、並びにその調製方法及びその使用

Resumen de: MX2024003496A

Disclosed are a composition containing 7-ethyl-10-hydroxycamptothecin, and a preparation method therefor and the use thereof. The composition contains SN-38, a lipid, albumin and Span 20.

PHARMACEUTICAL COMPOSITION, PREPARATION AND USES THEREOF

Resumen de: EP4431155A2

The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and of (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm and its absolute surface charge value is of at least 10 mV (|10 mV|). The carrier is in addition devoid of any surface sterically stabilizing agent. The invention also relates to such a composition for use for administering the pharmaceutical compound(s) in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one carrier comprising the at least one pharmaceutical compound are to be administered separately in a subject in need of said pharmaceutical compound, typically between more than 5 minutes and about 72 hours one from each other.

LIPID COMPOSITION AND SUBSTANCE DELIVERY METHOD

Resumen de: EP4431085A1

According to an arrangement, a lipid composition is for delivering an objective substance (3) to a target cell. The composition is contacted with the target cell under an environment of 37°C or higher. The composition includes a substance delivery carrier having lipid particle (1) and an objective substance (3) encapsulated in the lipid particle (1). The lipid particle (1) constitutes a liposome and includes FFT-10 and/or FFT-20 as constituents thereof.

BIOMARKERS OF MEGAKARYOCYTE-DERIVED EXTRACELLULAR VESICLES

Resumen de: AU2022386233A1

Disclosed herein are compositions and methods related to megakaryocyte-derived extracellular vesicles derived from human pluripotent stem cells, where the megakaryocyte-derived extracellular vesicles present unique biomarkers.

IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY

Resumen de: AU2022387111A1

The present disclosure describes compounds of Formula (I) and pharmaceutically acceptable salts thereof.

CATIONIC LIPID

Nº publicación: EP4431489A1 18/09/2024

Solicitante:

TAKEDA PHARMACEUTICALS CO [JP]
Takeda Pharmaceutical Company Limited

Resumen de: EP4431489A1

The present invention provides a technique capable of transferring an active ingredient, particularly, a nucleic acid, to a cell with excellent efficiency and/or to various cells and a cationic lipid for use in this technique, etc. The cationic lipid of the present invention is a compound represented by the following formula (I) or a salt thereof. In the formula (I), W represents -NR¹R² or -N⁺R¹¹R¹²R¹³ (Z^-), R¹ and R² each independently represent H or an optionally substituted C_1-5 alkyl group, R¹¹, R¹² and R¹³ each independently represent an optionally substituted C_1-5 alkyl group, Z- represents an anion, X represents an optionally substituted C_2-6 alkylene group, R^A and R^B each independently represent an optionally substituted C_1-17 alkyl group, an optionally substituted C_3-17 alkenyl group, an optionally substituted C_15-17 alkadienyl group, -R³-C (O)O-R⁴ or - R³-OC(O)-R⁴, R^C represents -R<sup>3</sup&